Kornimate/medical-research-clean huggingface dataset:
the effect of surgeon emotional support on treatment choice for low-risk thyroid cancer

Conditions: Thyroid Cancer; Thyroid Nodule; Benign Thyroid Nodule

Summary: 118 adults with benign thyroid nodules who were seen at a uw health clinic for a fine needle biopsy and do not need surgery will be enrolled and can expect to be on study for a one-time visit of up to 60 minutes. each participant will be randomized to watch one of two videos simulating a patient-surgeon discussion about treatment options for low-risk thyroid cancer with or without emotionally supportive statements.

in this study, the investigators will test the extent to which emotionally supportive communication from a surgeon is associated with patient preference for total thyroidectomy. the investigators will conduct a hypothetical choice experiment with "analogue" patients, defined as those with a benign thyroid nodule not requiring surgery. baseline measures will be collected, then participants will be randomized to watch a video simulation of a patient-surgeon discussion about treatment options for low-risk thyroid cancer with or without emotionally supportive statements. the investigators hypothesize that increased emotionally supportive communication by the surgeon will decrease the likelihood of patients choosing total thyroidectomy, reduce anxiety and thyroid cancer fear, and increase decisional confidence, perceived physician empathy, trust in physician, and information recall.

Eligibility criteria:
inclusion criteria (determined during electronic medical record (emr) screening): * seen in a uw health clinic for fine needle aspiration (fna) of a thyroid nodule in the last 30 days * thyroid nodule measures ≤4 centimeters * benign thyroid nodule biopsy result * able to speak and read english * access to internet inclusion criteria (determined/reconfirmed during pre-study screening on qualtrics): * seen in a uw health clinic for fna of a thyroid nodule in the last 30 days exclusion criteria (determined during emr screening): * additional thyroid nodule biopsy results that are not benign * history of thyroid cancer * history of thyroid surgery * has seen a surgeon about thyroid or parathyroid surgery * has a referral to see a surgeon about thyroid surgery * deaf * blind * vulnerable populations such as prisoners exclusion criteria (reconfirmed during pre-study screening on qualtrics): * history of thyroid cancer * history of thyroid surgery * has seen a surgeon about thyroid or parathyroid surgery * plans to see a surgeon about thyroid surgery

Keywords: thyroid cancer low-risk thyroidectomy emotional support treatment
an extension study in participants with moderate to severe rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study. the study provides 7 years of additional treatment with baricitinib.


Eligibility criteria:
inclusion criteria: * have completed the final active treatment in study jadv (nct01710358), jadz (nct01711359), jadx (nct01721057), jadw (nct01721044), jada (nct01185353) or jags (nct02265705) exclusion criteria: * have significant uncontrolled cerebro-cardiovascular (eg, myocardial infarction \[mi\], unstable angina, unstable arterial hypertension, severe heart failure, or cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neuropsychiatric disorders, or abnormal laboratory values that developed during a previous baricitinib study that, in the opinion of the investigator, pose an unacceptable risk to the participant if investigational product continues to be administered * have a known hypersensitivity to baricitinib or any component of this investigational product * had investigational product permanently discontinued at any time during a previous baricitinib study * had temporary investigational product interruption at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for participation in the study * have any other condition that, in the opinion of the investigator, renders the participant unable to understand the nature, scope, and possible consequences of the study or precludes the participant from following and completing the protocol
pharmacokinetic study of valaciclovir hydrochloride tablets

Conditions: Virus Diseases

Summary: valaciclovir (vacv), the l-valyl ester prodrug of aciclovir (acv), is extensively converted to acv and l-valine after oral administration. in subjects with normal renal function, acv is predominantly eliminated unchanged in the urine, with a small proportion metabolized to 9-carboxymethoxymethylguanine (cmmg). the metabolism of acv to cmmg is thought to involve aldehyde dehydrogenase (aldh). on the basis of a high proportion of the japanese population having low-activity aldh, it can be hypothesized that the conversion of acv to cmmg is decreased, thereby leading, in patients with renal impairment, to higher plasma concentrations of acv. this pilot study was conducted to investigate potential relationships between genetic polymorphisms of aldh2, an isozyme of aldh, and the plasma pharmacokinetics (pk) of vacv, acv and cmmg in subjects with end-stage renal disease on hemodialysis.


Eligibility criteria:
inclusion criteria: * japanese subjects with chronic renal failure undergoing hemodialysis regularly three times a week for at least 12 weeks prior to the start of the study. exclusion criteria: * subjects with current alcohol dependence. * subjects with gastrointestinal dysfunction that may affect drug absorption. * subjects who have received an organ transplant (however, subjects with a corneal transplant or any other organ transplant that may not affect the objectives of the study will be eligible for inclusion in this study).

Keywords: valaciclovir hydrochloride hemodialysis patient aldh pharmacokinetics japanese
predicting intubation of patients hospitalised for acutely attacked asthma

Conditions: Intubation Complication; Asthma

Summary: although the asthmatic treatments currently be effective in term of efficacy of inhaled medications and good clinical outcome including symptom controlled and asthma exacerbation number, the large number of worse event still have been reported. few cases eventually have been intubated and died even though using optimal medication. in this study, we will search to identify factors that may influence intubation in hospitalised patient with asthmatic attack.


Eligibility criteria:
inclusion criteria: * patients who had been admitted and diagnosed as asthmatic attack between year 2016-2018. * patients who have age \> 15 year old. exclusion criteria: * non
low density lipoprotein (ldl) cholesterol metabolism in impaired glucose tolerance

Conditions: Impaired Glucose Tolerance

Summary: impaired glucose tolerance is associated with an increased risk of developing cardiovascular disease and atherosclerosis for reasons not yet totally understood. previous studies evaluated the kinetics of plasma ldl and a faster removal rate of free cholesterol in normolipidemic patients with diagnosed arterial coronary disease and deposits of this cholesterol on the blood vessel walls. this disassociation of the cholesterol may suggest a new mechanism for not only the genesis but for the progression of arterial coronary disease. the objective of this research was to study the plasma kinetics of free cholesterol and cholesterol ester in impaired glucose tolerance patient, asymptomatic for coronary artery disease (cad), to elucidate mechanisms involved in atherogenesis in these patients.

along with hyperglycemia, the presence of obesity and dyslipidemia, risk factors associated with the natural onset of diabetes mellitus type 2, could possibly explain the high susceptibility of the glucose intolerance to cardiovascular disease. dyslipidemia commonly linked to glucose intolerance is characterized by hypertriglyceridemia, low hdl-c and in spite of the ldl-c being apparently normal or slightly elevated, there is presence of small dense ldl. formulated in the laboratory, an artificial lipid nanoemulsion marked with both 14c-cholesterol ester and 3h-cholesterol with lipid composition similar to ldl allows study the plasma kinetics of the two forms of cholesterol (free and esterified. the nanoemulsion mimics the natural ldl, but is prepared without protein. in contact with the bloodstream, the nanoemulsion acquires apolipoproteins, apo e preferentially, allowing it to be recognized and removed from plasma by ldl receptor. the application of this nanoemulsion was shown to be technically safe, appropriate and simple to be used in humans in order to understand the role of dyslipidemia in the atherogenic process.

Eligibility criteria:
inclusion criteria: * total cholesterol \< 6mmol/l * ldl-c \< 4mmol/l * triacylglycerides \< 2.2mmol/l * with normal blood pressure or hypertension until 130/85 mmhg exclusion criteria: * presence of previous cardiovascular disease: macrovascular, peripheral arterial disease and cerebral stroke. * presence of chronic disease: chronic renal failure (creatinin \>30 ug/mg), hepatic failure, asthma, chronic obstructive pulmonary disease, inflammatory disease, oncology and thyropathy compensated. * use of drugs: statins, fibrates, glucocorticoids and metformin
pilot study of the effect of ibudilast on neuroinflammation in methamphetamine users

Conditions: Methamphetamine-dependence

Summary: addiction to methamphetamine is a serious health problem in the united states. right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. more research is needed to develop drugs for methamphetamine addiction. ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.

addiction to methamphetamine is a serious health problem in the united states. right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. more research is needed to develop drugs for methamphetamine addiction. ibudilast (the study drug) is a drug that could help people addicted to methamphetamine. the investigators are interested to know if the study drug can help some symptoms that methamphetamine can cause, specifically inflammation in the brain. inflammation has been shown to affect decision-making. the study drug has anti-inflammatory properties, however it is not yet known whether the drug will reduce inflammation in the brain.

Eligibility criteria:
inclusion criteria: * abstinent from all drugs except marijuana and methamphetamine and have a negative urine drug screen on test days * meet diagnosis for recent methamphetamine-use disorder (dsm-v) or does not meet any substance-use disorders exclusion criteria: * known sensitivity to ibudilast * left handed * mri contraindications * clinically significant neurological, endocrine, renal, hepatic, or systemic diseases that would compromise safe participation or confound outcomes * any psychiatric diagnoses or primary psychotic or mood disorders (past depression diagnoses allowed) * any drug use disorder diagnosis besides methamphetamine or tobacco * any recreational or prescriptive use of psychotropic medications * claustrophobia * women who are pregnant or breast-feeding * neurodegenerative diseases that present with neuroinflammation * more than 4 weeks abstinent from methamphetamine * rs6971 genotype that confers low translocator protein (tspo) binding affinity to prevent unnecessary radiation exposure * liver disease requiring medication or medical treatment and/or aspartate or alanine aminotransferase levels greater than 3 times the upper limit * participation in any drug study in the last 3 months

Keywords: ibudilast methamphetamine neuroinflammation
study to investigate the efficacy and safety after administration of daewoong zoledronic acid for the purpose of treatment or prevention of osteoporosis

Conditions: Osteoporosis

Summary: this study is a non-interventional observational study. on the baseline (visit 1), we collect demographic data from all participating subjects according to their daily medical conditions, prescribe drugs and collect validity and safety data according to the research plan in visit 1 and visit 2. in addition, we collect data by application on subject's self-awareness symptoms and subject's questionnaire for medical outcome short form health survey (sf-36) every day from the baseline for 4 days.

the investigator will enroll subjects according to inclusion/exclusion criteria after obtaining informed consent form from each subject. enrolled subjects will administer zoledronic acid 5mg/100ml once on baseline (visit 1). the demographic data, prescription data, and medical history, etc will be collected based on the approved protocol. additionally using application, subject's self-awareness symptoms and subject's questionnaire for medical outcome short form health survey (sf-36) every day from the baseline for 4 days will be collected. investigator will also collect any occurrence of fracture through electronic medical record until 48 weeks (visit 2) from baseline visit.

Eligibility criteria:
inclusion criteria: 1. male and female adults 19 years of age or older at the time of screening visit 2. a person who is scheduled to administer the research drug according to the medical judgment of the researcher based on the permission 3. a person who can understand the information provided to the person and can voluntarily sign a written consent form exclusion criteria: 1. those subject to contraindications to administration according to the drug approval requirements for research * patients with hypersensitivity to the components of this drug or other bisphosphonate drugs hypocalcemia * patients with severe renal impairment whose creatinine clearance rate is less than 35 ml/min (patients must measure serum creatinine and creatinine clearance before receiving the study drug). * patients receiving zometa for cancer as an indication * pregnant women, women who may be pregnant, and lactating women 2. patients participating in other clinical trials (however, registration is possible if you have not received investigational drugs or are participating in other non-interventional observational studies.) 3. in addition to the above, patients whom the researcher (physician in charge) determines are not suitable as subjects of this observational study.
intraoperative optical coherence tomography for ophthalmic surgical guidance - cornea

Conditions: Corneal Transplantation

Summary: optical coherence tomography (oct) image data will be evaluated for image quality and used to test post-processing algorithms to improve detection sensitivity for ophthalmic diseases.

optical coherence tomography (oct) is an established technology for ophthalmic diagnosis which can perform noncontact, noninvasive, real time, cross-sectional imaging of the retina and anterior eye. oct has displaced ophthalmoscopy and stereo-photography as the gold-standard for clinical assessment and documentation of retinal microanatomy including thickness, cystoid structures, subretinal fluid and retinal traction. despite these benefits, new technologies can still benefit patients including increasing the resolution, imaging speed, and contrast of oct technologies. since 2013, dr. tao's group has worked to develop and translate new ophthalmic imaging technologies. the goal of this proposal is to develop novel oct technology for improved diagnostic sensitivity in ophthalmology. specifically, the investigators will develop novel oct imaging and image-processing methods to improve imaging speed and quality. successful completion of this project will improve clinical diagnostics of ophthalmic diseases. pre-clinical validation of system performance and ergonomics is a valuable step is clinical imaging technology development. the aim of this project is to performance system iterations on next-generation ophthalmic oct imaging technologies over current-generation imaging systems on healthy adult volunteers prior to clinical translation. while system resolution, contrast, and speed can be (and will be) evaluated using calibration standards and phantoms, in vivo human imaging in healthy subjects is necessary to establish a baseline for system performance and image quality prior to clinical translation.

Eligibility criteria:
inclusion criteria: * adults (\>18 years) with diagnosis of cornea transplant (keratoplasty) exclusion criteria: * children or adults unable to consent * healthy adults (\>18 years) without diagnosis of cornea transplant (keratoplasty)

Keywords: optical coherence tomography ophthalmology cornea
a study evaluating if pridopidine is safe, efficacious, and tolerable in patients with huntington's disease

Conditions: Huntington's Disease

Summary: the purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with huntington's disease (hd).


Eligibility criteria:
inclusion criteria: * pride hd completion within the last 6 months, including 2 week follow up period or patients who transitioned from the open hart study or patients who complete future safety and efficacy clinical trials of pridopidine. in addition, patients who have already completed their defined study period under open pride hd global or local amendments and have discontinued treatment with pridopidine will be allowed to re enter the open pride hd study. * women of child bearing potential or male participants: adequate contraception and birth control * good general health * other criteria apply, please contact the investigator for more information exclusion criteria: * similar baseline criteria for ecg, vital signs, cardiovascular system, and renal function to pride hd; * similar concomitant medication restrictions to pride hd. * other criteria apply, please contact the investigator for more information

Keywords: huntington's disease, pridopidine
ranibizumab as adjuvant therapy for the treatment of choroidal melanoma (cohort 2)

Conditions: Choroidal Melanoma

Summary: ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with choroidal melanoma. the investigators consider that higher doses of ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.


Eligibility criteria:
inclusion criteria: * 18 years or older * primary pigmented or amelanotic choroidal melanoma measuring 16 mm or less in the largest basal diameter and 6 mm or less in the apical height. * location of the tumor, posterior to the equator of the eye. * documented growth of tumor by a-b scan. * ability to provide written informed consent and comply with the study assessment for the full duration of the study. exclusion criteria: * pregnancy or lactation. * premenopausal women not using adequate contraception. * current infection or inflammation in either eye. * extension of tumor into the orbit. * regional spread or metastatic disease. * any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated. * any known allergy to any of the components to be used in the study. * participation in another simultaneous medical investigation or trial.

Keywords: choroidal melanoma ranibizumab transpupillary thermotherapy cstip indocyanine green
the northstar trial

Conditions: Flutter, Atrial

Summary: the introduction of real-time mri-guided cardiac ablation therapy, a significant advancement in interventional medicine, necessitates precise catheter tracking for accurate navigation within the complex cardiac anatomy. the introduction of the northstar software as an active tracking system holds promise for improving the precision and efficiency of catheter manipulation during these procedures. however, a rigorous evaluation of its accuracy and reliability in a clinical setting is crucial to validate its viability. the objective of this study is to evaluate the accuracy of catheter localization using the northstar software during real-time mri-guided cardiac ablation therapy.


Eligibility criteria:
inclusion criteria: * patients undergoing a real-time mri-guided flutter ablation procedure at the amsterdam umc. exclusion criteria: * lack of legal capacity. * insufficient proficiency in the dutch language.
health-related quality of life in korean patients with rheumatic diseases

Conditions: Scleroderma, Systemic

Summary: to compare the health related quality of life of patients with systemic sclerosis with other rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus and sjogren's syndrome.

systemic sclerosis (ssc) is a connective tissue disease characterized by vasculopathy, fibrosis, and autoimmunity. the prognosis of the disease depends on the nature and severity of organ involvement. patients with ssc suffer from digital ulceration, arthritis, progressive skin tightening, and joint contractures that cause pain and limitation of limb function. the cardiopulmonary system may also be severly affected by ssc in the form of interstitial lung disease and pulmonary arterial hypertension, which leads to reduction in exercise capacity and symptomatic dyspnea. gastrointestinal involvement by ssc may cause malnutrition, and ssc renal crises may result in renal failure. in addition, cosmetic disfigurement resulting from facial and limb skin involvement may lead to social isolation, mood problems, and significant work disability. it has been reported that health related quality of life (hrqol) is significantly impared in ssc patients compared to the general population. moreover, the degree of impairment in ssc patients was comparable to those who suffered from other chronic illnesses such as heart and lung disease, hypertension, diabetes mellitus, and depression. however, there were no studies yet comparing the hrqol of ssc patients with other rheumatic diseases, such as rheumatoid arthritis (ra) and systemic lupus erythematosus (sle). especially, information regarding the impact of ssc on functioning and hrqol in korean patients is lacking. therefore, the investigators plan to compare the functioning and hrqol of patients with ssc with other rheumatic diseases, such as ra, sle, and sjogrens's syndrome, and healthy controls. a validated korean version of the medical outcomes study short form 36 (sf36) questionnaire and the euroqol five dimensions questionnaire (eq-5d) will be used in this study.

Eligibility criteria:
inclusion criteria: * males or females \> 18 years at time of consent * patients able to understand written and spoken korean * patients who have been informed about the research * patients with ssc meeting the 1980 acr criteria or 2013 acr/eular criteria for ssc * patients with ra meeting the 2010 acr/eular criteria * patients with sle meeting the 1997 acr criteria or 2012 slicc criteria * patients with sjogren's syndrome meeting the 2002 aecg criteria or 2012 acr criteria * controls : without any rheumatic diseases exclusion criteria: * severe mental retardation * any impairment of ability to understand making self-evaluation impossible (using a validated korean version of the sf36 and eq-5d) * anyone with other rheumatic diseases